Clinical trials: Alzheimer Disease
Alzheimer Disease
Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease
To explore whether dietary supplementation with a version of Anatabloc(R) exerts an effect on blood levels of amyloid beta (Aβ), or impacts global or functional measures of Alzheimer's Disease (AD) in subjects with mild to…
- Trial name
- ASAP (NCT01669876)
- Testing
- Anatabloc(R)
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Rock Creek Pharmaceuticals, Inc.
Alzheimer's Disease
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
Approximately 90 patients, aged 50 to 80 years, with a diagnosis of early Alzheimer's disease will take part in this research study. This study will be conducted in the US.
- Trial name
- EAD501 (NCT05607615)
- Testing
- Hydroxypropyl Beta Cyclodextrin
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Cyclo Therapeutics, Inc.
Alzheimers Disease
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to…
- Trial name
- NCT04639050
- Testing
- RO7126209
- Where
- 37 sites in United States, Australia and 7 more
- Volunteers
- 241 people
- Sponsor
- Hoffmann-La Roche
Alzheimers Disease
The Feasibility of Florbetapir Quantitation
The overall objective of the study is to assess the feasibility of implementing a quantitative process of florbetapir F 18 scan interpretation.
- Trial name
- NCT01946243
- Testing
- Florbetapir F18
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease
The purpose of this study is to find optimistic dose and to evaluate the efficacy and safety of SK-PC-B70M in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00443417
- Testing
- SK-PC-B70M
- Where
- South Korea
- Volunteers
- 188 people
- Sponsor
- SK Chemicals Co., Ltd.
Alzheimer's Disease
Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease
The study is designed to investigate the efficacy, safety and tolerability of SB-742457 versus placebo in subjects with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00708552
- Testing
- SB-742457, Donepezil
- Where
- 72 sites in Bulgaria, Chile and 9 more
- Volunteers
- 576 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)
The study investigated the effects on safety and pharmacokinetics (PK) of MK-1942 and donepezil when co-administered to participants with Alzheimer's Disease with mild-to-moderate cognitive impairment stably treated with…
- Trial name
- DDI (NCT04308304)
- Testing
- MK-1942, Donepezil
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease (AD)
Recombinant Human Serum Albumin in the Treatment of Mild-to-moderate AD (Alzheimer's Disease) Exploratory Clinical Trial
This clinical trial is an open-label, parallel-group, exploratory study of recombinant human serum albumin in patients with mild to moderate Alzheimer's Disease (AD).
- Trial name
- NCT06489015
- Testing
- Recombinant Human Serum Albumin
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Protgen Co., Ltd.
Alzheimer's Disease
Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
- Trial name
- CONCERT (NCT00829374)
- Testing
- Dimebon
- Where
- 101 sites in United States, Australia and 8 more
- Volunteers
- 1,003 people
- Sponsor
- Medivation, Inc.
Alzheimer Disease, Dementia
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- MINDFuL (NCT05318976)
- Testing
- XPro1595
- Where
- 41 sites in Australia, Canada and 6 more
- Volunteers
- 207 people
- Sponsor
- Inmune Bio, Inc.
Alzheimer's Disease
A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of JNJ-54861911 during 6 months of treatment in participants with early (predementia) alzheimer's disease (AD [degenerative disease of the brain…
- Trial name
- NCT02260674
- Testing
- JNJ-54861911, 10 milligram (mg), JNJ-54861911, 50 mg
- Where
- 19 sites in Belgium, France and 4 more
- Volunteers
- 114 people
- Sponsor
- Janssen Research & Development, LLC
Alzheimer Disease, Cognition Disorders
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease…
- Trial name
- NCT00000174
- Testing
- Rivastigmine
- Where
- 15 sites in United States
- Sponsor
- Novartis
Alzheimer's Disease
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
This study in individuals with early Alzheimer's disease is designed to assess:(1) safety and tolerability (2) the capacity of ACC-001 and QS-21 adjuvant to reduce brain amyloid load as measured by positron emission tomography…
- Trial name
- NCT01227564
- Testing
- ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg
- Where
- 40 sites in United States
- Volunteers
- 63 people
- Sponsor
- Pfizer
Alzheimer Disease
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease
The purpose of this study is to assess the safety and tolerability of JNJ-63733657 following single ascending intravenous (IV) dose administration in healthy subjects (Part 1) and multiple ascending IV dose administrations in…
- Trial name
- NCT03375697
- Testing
- JNJ-63733657
- Where
- 7 sites in Belgium, Germany and 2 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Alzheimer's Disease
Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
This study will evaluate compliance, tolerability, safety, efficacy and caregiver burden of rivastigmine patch 10 cm² treatment in people with Alzheimer's disease (MMSE 10-26) initiating therapy for the first time with a…
- Trial name
- CARE (NCT00731224)
- Testing
- Rivastigmine transdermal patch
- Where
- 40 sites in Australia, Malaysia and 3 more
- Volunteers
- 380 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed AVA105640.
- Trial name
- NCT00550420
- Testing
- Rosiglitazone XR
- Where
- 70 sites in United States, Austria and 16 more
- Volunteers
- 331 people
- Sponsor
- GlaxoSmithKline
Alzheimer Disease, Dementia
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
- Conditions
- Alzheimer Disease, Dementia, Plaque, Amyloid
- Trial name
- NCT07602582
- Testing
- Donanemab
- Where
- 62 sites in United States, Japan and 1 more
- Volunteers
- 550 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease (AD)
A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355
The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of CKD-355.
- Trial name
- NCT03802162
- Testing
- CKD-355A (D797/Memantine HCl 20mg), CKD-355B (D797/Memantine HCl 20mg), D797
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Alzheimer's Disease
Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers
Rilapladib is a potent and selective inhibitor of lipoprotein associated phospholipase A2 (Lp-PLA2), which was previously under development for the treatment of atherosclerosis and is currently being developed for the treatment…
- Trial name
- NCT02130661
- Testing
- Rilapladib 25 mg, Rilapladib 250 mg, Itraconazole
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)
MK0952 is a phosphodiesterase type IV (PDE4) inhibitor in development for improvement of cognitive impairment in mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00362024
- Testing
- MK0952
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.